Investors in Recursion (NASDAQ: RXRX) seemed only mildly fazed by Wednesday’s series of company announcements. The artificial intelligence (AI)-based drug developer’s stock barely moved on Wednesday, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results